Let’s take a close look at PARADIGM-HF
10 years later here is the original un-redacted debate between Milt Packer and myself
Related Articles
City of Hope Buys 52 Acres in Orange County for $89M
The cancer treatment network paid $108M in 2020 for 11 acres and a 190K-SF building there to build its Lennar Foundation Cancer Center.
Seminal Trials: IPASS for EGFR NSCLC | IASLC
In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator,…
Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer | JCO Oncology Practice
PURPOSEFinancial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with…
What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma | Research To Practice
Friday, December 6, 2024, San Diego, California, 3:15 PM – 5:15 PM PT (6:15 PM – 8:15 PM ET) Program Schedule — Pacific Time 2:45…
Toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer: A secondary analysis of the LUSTRE randomized trial
Stereotactic body radiotherapy (SBRT) is increasingly used to treat early-stage non-small cell lung cancer (NSCLC) in medically inoperable patients. Excellent rates of local control (87 %-95 %)…
The AI-Empowered Oncologist: A Look Back at ASCO24 Research to Improve Clinical Use
The use of artificial intelligence (AI) was a central theme at the 2024 ASCO Annual Meeting, including many tools, such as large language models, clinical…
Creating a World Where Precision Oncology is a Reality for All
Vivek Subbiah, MD, of Sarah Cannon Research Institute, explains what areas need to be addressed to make precision oncology more accessible.
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer – OncoDaily
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer / cancer, dMMR/MSI-H Rectal Cancer, Dostarlimab, FDA, OncoDaily, Oncology,
Jean-Charles Soria: How FcγR engagement influences antibody efficacy, toxicity and pharmacokinetics – OncoDaily
Jean-Charles Soria: How FcγR engagement influences antibody efficacy, toxicity and pharmacokinetics / Alvaro Sebastian, Aurélien Marabelle, cancer,
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non‐seminomatous germ cell tumour
Objectives To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a,…
